AI vendor decisions rarely fail because of a weak demo. They fail because the buying team approved speed, promise, and usability before it had enough evidence on data exposure, control maturity, accountability, and regulatory fit. If you are working through how to evaluate AI vendors in healthcare or another regulated environment, the real question is not whether a platform looks capable. It is whether the vendor can support your use case without creating governance debt you will have to explain later.
That distinction matters at the executive level. Once AI tools touch protected health information, customer records, internal knowledge bases, or operational decision-making, vendor selection becomes a board-level risk decision. Security, legal, compliance, IT, and business leadership all have a stake, and each group is trying to answer a different version of the same question: can we defend this choice under scrutiny?
How to evaluate AI vendors in a regulated business
A disciplined review starts by defining the use case before you assess the market. Many AI procurement efforts become noisy because teams compare vendors that are solving different problems. One platform may be a workflow assistant, another may be a model provider, and a third may be a document automation layer with embedded AI. If your team has not clearly documented the intended use, the data involved, the users, the expected outputs, and the level of decision impact, you will end up evaluating product marketing instead of actual risk.
This is where leadership should set the frame early. Decide whether the AI tool will inform decisions, automate tasks, generate external-facing content, support clinical or financial workflows, or process sensitive records. Then establish what would make the deployment unacceptable. That might include sending data to public models, a lack of tenant isolation, weak subcontractor oversight, no audit logging, or unclear retention terms. When those guardrails are defined up front, vendor conversations become more productive and procurement becomes much easier to defend.
The strongest evaluation models do not treat every vendor the same. A low-impact productivity tool should not receive the same level of scrutiny as an AI system that processes PHI or influences care operations. A risk-based approach lets teams move faster where the exposure is limited and go deeper where legal, security, or operational consequences are materially higher.
Start with governance, not features
Executive teams often ask product leaders whether a vendor is the best tool available. That is a useful question, but not the first one. The first question is whether the vendor operates with enough discipline to fit your governance environment.
A credible AI vendor should be able to explain who owns model risk, how changes are reviewed, how training and inference data are handled, how customer environments are separated, and what documentation exists for incident response, access control, and model updates. If those answers are vague, heavily qualified, or dependent on future roadmap commitments, treat that as signal. In regulated settings, immaturity rarely stays contained to one area.
You should also look for signs that the vendor understands enterprise accountability. Can they support contract language around data handling? Do they have clear escalation paths? Can they identify their subprocessors and describe where data is stored and processed? Do they distinguish between customer data, telemetry, prompts, outputs, and model improvement data? Those details matter because they shape both compliance exposure and internal stakeholder confidence.
Security and compliance questions that actually matter
When teams discuss how to evaluate AI vendors, they often default to generic security questionnaires. Those still have value, but AI creates additional layers that standard software reviews may miss.
The practical issue is not simply whether a vendor has a SOC 2 report or encryption at rest. It is whether their control environment addresses the specific risks introduced by AI workflows. That includes prompt handling, model access, output monitoring, data residency, human review, testing for harmful or inaccurate outputs, and restrictions on secondary data use.
For healthcare and other regulated organizations, the review should go further. If the vendor will handle PHI, can they support a business associate agreement? If they claim HIPAA alignment, ask what that means operationally. Many vendors use compliance language loosely. You need to know whether they have implemented the administrative, technical, and contractual controls required for the actual deployment model.
It is also wise to examine the boundary between the vendor's responsibilities and yours. Some AI providers offer secure infrastructure but place output validation, role-based access design, retention controls, or user oversight entirely on the customer. That does not make them unusable, but it changes the implementation burden and the residual risk. A sound evaluation makes that division explicit.
How to evaluate AI vendors beyond the sales narrative
The fastest way to get clarity is to test claims against operating evidence. Ask for current documentation, not aspirational statements. Review security materials, privacy terms, architecture diagrams, subprocessors, penetration testing summaries, model governance documentation, and incident response processes. If the vendor cannot produce consistent artifacts, your team should assume that governance maturity is limited.
This is also where reference checks become more valuable than polished demos. Ask how the vendor behaves after contract signature. Do they communicate material product changes? Are security reviews handled efficiently? Does the support team understand regulated customer requirements? Have there been surprises around data usage, logging, or product behavior? In AI, post-sale operational trust is often more important than pre-sale functionality.
A pilot can help, but only if it is structured correctly. Do not run a proof of concept with live sensitive data before access, monitoring, retention, and contractual expectations are settled. Start with bounded use cases, clear success criteria, and named owners across security, legal, compliance, and the business. A pilot should reduce uncertainty, not create unmanaged exposure.
Evaluate the vendor's model of accountability
One of the biggest differences between traditional software vendors and AI vendors is the pace of change. Models evolve, features are released quickly, and dependencies may shift underneath the customer. That means your evaluation should include change management discipline.
Ask how model updates are introduced and communicated. Determine whether customers can opt out of certain features, whether material changes are documented, and whether you can restrict risky functionality by user group or deployment setting. If a vendor cannot provide meaningful administrative control, leadership is accepting more uncertainty than it may realize.
You should also examine whether the vendor can support audit readiness. If regulators, customers, investors, or your own board ask why this AI system was approved, what records will exist? Strong vendors make it easier to document risk review, security posture, intended use, and control ownership. Weak vendors leave customers assembling evidence from scattered emails and product screenshots.
This is one reason many organizations are formalizing AI vendor review within broader third-party risk management rather than treating it as a one-off innovation purchase. Infragil often sees avoidable friction when AI tools enter the environment outside established oversight processes and have to be retroactively governed. That path is slower, more expensive, and harder to defend.
The decision is not yes or no. It is yes, no, or not yet
A mature evaluation process leaves room for conditional approval. Some vendors are strategically valuable but not ready for enterprise-wide deployment. Others may be acceptable only for low-risk use cases or with compensating controls in place. Leadership should be comfortable saying not yet when the use case is strong but the evidence is incomplete.
That is especially true when internal enthusiasm is high. Pressure to move quickly can distort judgment, particularly when a business team sees immediate productivity upside. The role of governance is not to slow innovation for its own sake. It is to make sure the organization can scale AI adoption without accumulating avoidable legal, security, and operational problems.
The best vendor choice is rarely the one with the loudest market presence. It is the one whose technical capabilities, control environment, contractual posture, and operating discipline align with your risk tolerance and regulatory obligations. That answer will vary by use case, data sensitivity, and oversight expectations.
If your team wants a practical standard for how to evaluate AI vendors, aim for a process that produces evidence, not just impressions. The real deliverable is not a completed questionnaire or a successful pilot. It is a decision record your leadership team can stand behind six months later, when adoption expands and someone asks why this vendor was trusted in the first place.
That is the level of clarity that turns AI procurement from a reactive exercise into a defensible leadership decision.
Ready to Act?
Start Building a Stronger Vendor Risk Program
Skopos gives regulated organizations the tools to manage vendor risk with audit-ready workflows, AI-aware questionnaires, and real-time visibility.